Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.

ABSTRACT:

Background

Chemotherapy induced cardio-toxicity has been recognized as a serious side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity among patients with breast cancer is well studied but the impact on patients with sarcoma is limited, even though they are exposed to higher ANT doses. The commonly used term for cardio-toxicity is cancer therapeutics related cardiac dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF) reduction of > 10%, to a value below 53%. The aim of our study was to estimate the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the baseline risk factors and echocardiography parameters among that population.

Methods

Data were collected as part of the Israel Cardio-Oncology Registry (I

SUBMITTER: Shamai S 

PROVIDER: S-EPMC7325299 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature